



## Nanocarriers-Based Antimicrobial Drug Delivery

Guest Editor:

**Dr. Anisha D'Souza**  
Massachusetts Eye and Ear  
Infirmary, Harvard Medical  
School, Boston, MA, USA

Deadline for manuscript  
submissions:  
**closed (15 April 2024)**

### Message from the Guest Editor

Dear Colleagues,

Combating microbial infections is challenging due to the rapid development of multi-drug resistance. Microbial diseases can be contagious or infectious, resulting in short or chronic and long-lasting illnesses. Nanocarriers—polymer/lipid-based, liposomes, micelles, metal-based, silica, fullerenes, dendrimers, zeolites, quantum dots, hydrogels and composites—have been explored for antipathogenic, microbicidal, or microbiostatic properties in various microbial infections, including those arising from biofilms. Nevertheless, nanocarriers for intracellular or extracellular infections need to be designed appropriately to target specific microbes, alleviate the resistance of the drug–pathogen interaction and toxicity and disrupt biofilms as well as increase the scope in theranostics and cosmeceuticals.

In this Special Issue, manuscripts, both original research and reviews, concerning nanocarrier-based approaches for antimicrobial drug delivery-related areas of interest in human and veterinary medicine and in the food and agriculture industry are welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi